The European Society for Medical Oncology Gastrointestinal Cancers Annual Congress 2026 (ESMO GI 2026)
Munich, Germany 01 July 2026 - 04 July 2026
French study highlights atezolizumab–bevacizumab benefit in HCC
Four-year updates from the CHIEF study show a durable survival benefit with atezolizumab plus bevacizumab in individuals with advanced hepatocellular carcinoma (HCC).
French study highlights atezolizumab–bevacizumab benefit in HCC
08 Sep 2026
Real-world study supports new therapeutics for BRAF-mutant metastatic CRC
A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).
Real-world study supports new therapeutics for BRAF-mutant metastatic CRC
07 Sep 2026
Second-line adagrasib plus cetuximab falls short of extending survival in KRAS G12C-mutated mCRC
Second-line treatment with adagrasib plus cetuximab demonstrates manageable safety but results in no statistically significant improvement in both progression-free (PFS) and overall survival (OS) in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC) compared with chemotherapy, results of the KRYSTAL-10 trial have shown.
